Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q1 2023 · 10-Q
Revenue$21.62M$21.62M+400.7% vs Q1 2022 Net Income-$291.82M-$291.82MN/M vs Q1 2022 EPS Diluted-$0.38-$0.38N/M vs Q1 2022 Operating Income-$276,413,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
Free Cash Flowderived-$250,335,000N/M Margins · derivedOperating margin-1278.3%+5258.2 pt vs Q1 2022
Net margin-1349.5%+6333.0 pt vs Q1 2022
ended Jun 30, 2023 · filed Aug 14, 2023 · 45 d after period end